China Biologic passes GMP certification for new coagulation factor facility in China.
M2 EQUITYBITES-December 24, 2014-China Biologic passes GMP certification for new coagulation factor facility in China
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company China Biologic Products (NASDAQ:CBPO) reported on Tuesday the receipt of the Good Manufacturing Practices ("GMP") certification from the China Food and Drug Administration (the "CFDA") for its new coagulation factor production facility.
This certification was awarded to the company's majority-owned subsidiary, Shandong Taibang Biological Products Co. The company said the CFDA inspected this new facility for GMP compliance in June 2014.
With immediate effect, the company's new certified facility will primarily produce plasma-derived prothrombin complex concentrate, factor VIII and various other coagulation factors are in the pipeline. This new facility has the capability to produce multiple coagulation factors concurrently and on a larger scale compared with its existing production facilities.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Dec 24, 2014|
|Previous Article:||Cal-Maine Foods reports increased net income of USD36.6m in Q2 fiscal 2015.|
|Next Article:||Safeway announces completion of assets sale of its PDC subsidiary to Terramar Retail Centers for USD830m.|